Prof. Dr. Saadettin Kilickap

Prof. Dr. Saadettin Kilickap
Academic Title :
Prof. Dr.

Prof. Dr. Saadettin Kilickap is a Medical Oncology specialist at Liv Hospital Ankara, Department of Medical Oncology. He has extensive experience of over 20 years in the diagnosis and treatment of solid tumors and clinical cancer research.

Education and Academic Qualifications

  • Bachelor of Medicine, Faculty of Medicine, Gazi University, Turkey, 1992 - 1998.
  • Specialization in Internal Medicine, Faculty of Medicine, Hacettepe University, Turkey, 1998 - 2003.
  • Subspecialty in Medical Oncology, Cancer Institute, Hacettepe University, Turkey, 2003 - 2009.
  • Master's Degree in Cancer Epidemiology, Cancer Institute, Hacettepe University, Turkey, 2007 - 2009.

Areas of Interest

  • Medical Oncology
  • Lung cancer
  • Breast cancer
  • Colorectal cancer
  • Stomach cancer
  • Melanoma
  • Gastrointestinal system cancers
  • Sarcomas
  • Genitourinary system cancers
  • Head and neck tumors
  • Glial tumors
  • Cancer Epidemiology
  • Targeted therapies and immunotherapy
  • Resident and Researcher, Department of Internal Medicine, Faculty of Medicine, Hacettepe University, 1998 - 2003.
  • Specialist in Medical Oncology, Cancer Institute, Hacettepe University, 2003 - 2009.
  • Visiting Physician, Department of Hematology and Oncology, University of Regensburg, Germany, 2009.
  • Assistant Professor and Associate Professor, Department of Internal Medicine, Faculty of Medicine, Cumhuriyet University, 2009 - 2012.
  • Associate Professor, Cancer Institute, Department of Preventive Oncology, Hacettepe University, 2012 - 2016.
  • Professor, Cancer Institute, Department of Preventive Oncology, Hacettepe University, 2016 - Present.
  • Medical Director of Academic Affairs and Medical Oncology Specialist, Liv Hospital Ankara, Present.
  • Turkish Medical Oncology Association
  • Oncology and Immunotherapy Association
  • Turkish Internal Medicine Specialist Association
  • Academic Geriatrics Association
  • Medical Research and Education Association
  • National Cancer Advisory Board, Preventive Oncology Subcommittee
  • Turkish Medicines and Medical Devices Agency
  • "Risk assessment of febrile neutropenia and evaluation of G-CSF use in patients with cancer: a real-life study", 2020.
  • "Starting of biological disease modifying antirheumatic drugs may be postponed in rheumatoid arthritis patients with multimorbidity", 2018.
  • "Clinical outcomes of concomitant use of proton pump inhibitors and regorafenib in patients with metastatic colorectal cancer: a multicenter study", 2022.
  • "Real-world effectiveness and safety of brigatinib in advanced ALK-positive NSCLC: a nationwide multicenter study by the Turkish Oncology Group", 2026.
  • "Crizotinib efficacy and safety in patients with advanced NSCLC harboring MET alterations: A real-life data of Turkish Oncology Group".
Share :